PROTEOMTECH, INC.

Basic Information

PROTEOMTECH, INC.
5980 HORTON ST, STE 405
EMERYVILLE, CA, 94608

Company Profile

n/a

Additional Details

Field Value
DUNS: 110482911
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. p53 Fusion Protein as an Oncology Therapeutic

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): The aim of this proposal is to test the feasibility of the use of a p53 fusion protein as a cancer therapeutic. World wide 10 million people are diagnosed every ye ...

    SBIR Phase I 2007 Department of Health and Human Services
  2. Recombinant Des-Kringle Derivatives of Plasmin for Treatment of Peripheral Arteri

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Thrombolytic treatment with plasminogen activators (PA) such as tissue plasminogen activator (tPA) has been used not only for treatment of acute myocardial infarct ...

    SBIR Phase I 2006 Department of Health and Human Services
  3. Recombinant h-VEGI as an Anit-Angiogenesis Therapeutic

    Amount: $750,197.00

    DESCRIPTION (provided by applicant): Blocking or inhibiting tumor blood vessel growth (angiogenesis) remains a critical focal point for anticancer drug development. Studies on Vascular Endothelial ...

    SBIR Phase II 2004 Department of Health and Human Services
  4. Bioengineering Prourokinase for Improved Fibrinolysis

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): The objective of this proposal is to bioengineer a mutant variant of prourokinase (proUK) with improved therapeutic properties for treatment of acute myocardial in ...

    SBIR Phase I 2004 Department of Health and Human Services
  5. Recombinant HBxAg Production For Anti-cancer Therapeutic

    Amount: $100,000.00

    DESCRIPTION (provided by investigator): Chronic infection with hepatitis B virus (HBV) is associated with a high incidence of liver diseases, including hepatocellular carcinoma (HCC). Hepatitis B viru ...

    SBIR Phase I 2004 Department of Health and Human Services
  6. Recombinant h-VEGI as an Anticancer Therapeutic

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Blocking or inhibiting blood vessel growth (angiogenesis) remains a critical focal point for anticancer drug development. Studies on Vascular Endothelial Growth In ...

    SBIR Phase I 2003 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government